50% Covaxin efficacy may not be as bad as it seems

A study conducted by AIIMS has shown that two doses of Covaxin, the indigenous vaccine developed by Indian Council of Medical Research in collaboration with Bharat Biotech, is 50% effective in preventing symptomatic infection due to Covid-19. This is lower than the 77.8% efficacy claimed by Bharat Biotech after phase 3 trials of the vaccine.

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.